Michael Chambers is the President and CEO of Swift Biotech. He has been a life-long entrepreneur. He received B.A. and J.D. degrees from the University of Alabama and a Ph.D. from the University of Geneva in Switzerland. He was the recipient of a Rotary Ambassadorial Scholarship and a Swiss Confederation Fellowship. He speaks fluent French and Spanish.
Previously, Dr. Chambers helped establish InnoRx Pharmaceuticals in 1999, a company specializing in development of drugs and drug delivery systems for ocular disease. He served as President and CEO of InnoRx until negotiating its sale and merger into SurModics (NASDAQ: SRDX) in January 2005.
Swift was one of three winners, among 50 competitors, of the 2010 Alabama Launchpad Business Plan competition for new technologies. Swift is developing several technologies in collaboration with the Mitchell Cancer Institute, including screens for endometrial and ovarian cancer, two of the leading causes of death in women in the United States.
He actively invests in early stage high growth companies and serves on several boards of directors, including ProUroCare, a publicly traded company based in Minneapolis, and InQ Biosystems, based in Huntsville, Alabama.
He is currently working with others to organize angel investment networks and coordinate their activities with throughout Alabama and the Southeast. He was selected to serve as a member of the team authoring the commercialization component of the Alabama Science & Technology Roadmap, commissioned by the Governor, which seeks to spur economic development in this area.
Active in the community, he serves or has served on various boards of directors, including Rotary, the Rotary Children’s Foundation, the YMCA, Goodwill-Easter Seals, the Mobile Area Chamber of Commerce Board of Advisors, Pritchard Preparatory School and the Presbyterian Home for Children. He is past president of the Rotary Club of Mobile where he is a Paul Harris Fellow, a Major Donor and chair of the District Committee on Health & Hunger.